Trump’s Tylenol Warning Linked to Autism Treatment Shifts
Recent research indicates a decline in Tylenol (acetaminophen) use among pregnant women following public statements made by former President Donald Trump linking the common pain reliever to autism. Simultaneously, prescriptions for the generic drug leucovorin saw a significant increase for children during the same period.
In September 2025, President Trump publicly advised pregnant women against taking Tylenol, promoting unproven connections between the medication and autism spectrum disorder. He also championed leucovorin as a potential treatment for autism. A study published in , in the medical journal The Lancet, examined the impact of these statements on medication ordering patterns.
The study, which analyzed data from over 1,633 hospitals and 37,000 clinics encompassing approximately 294 million patients, revealed a 10% decrease in Tylenol orders for pregnant patients aged 15 to 44 in emergency departments after the White House briefing. Conversely, outpatient prescriptions for leucovorin among children aged 5 to 17 increased by 71% during the same timeframe, from late September to early December. Researchers observed no comparable shifts in prescriptions for other medications, suggesting a direct correlation to the presidential announcement.
“It just shows that in our country right now, health care has been politicized in a way that political messages are driving and impacting care — and not always for good,” stated Dr. Susan Sirota, a pediatrician in Highland Park, Illinois, who was not involved in the research. This observation highlights a concerning trend of non-medical factors influencing healthcare decisions.
It’s important to understand the context surrounding these medications. Acetaminophen, commonly known as Tylenol, is frequently used by pregnant women to manage pain and fever. Untreated fevers, particularly during the first trimester, can increase the risk of miscarriage, preterm birth, and other complications, according to the Society for Maternal-Fetal Medicine. While some studies have explored a possible association between acetaminophen use during pregnancy and autism risk, the majority have not established a definitive link.
Leucovorin, a derivative of folic acid, is primarily used to mitigate the toxic side effects of certain chemotherapy drugs and to treat a rare blood disorder. It has also been investigated for cerebral folate deficiency and, in limited studies, for a subset of children with autism. However, the American Academy of Pediatrics does not recommend routine leucovorin use for autism, citing limited evidence and potential side effects, which can include irritability, nausea, vomiting, and skin reactions.
The study authors acknowledge certain limitations. The data primarily reflects Tylenol use in emergency department settings and doesn’t capture over-the-counter purchases. Despite this limitation, the researchers found the rapid and significant changes in prescribing patterns to be noteworthy. Dr. Michael Barnett, a co-author of the study and professor of health services, policy and practice at the Brown University School of Public Health, noted the speed of the response was “surprising,” indicating a swift shift in both public and clinical behavior following the announcement.
The findings underscore the potential impact of public officials’ statements on healthcare practices. Dr. Barnett emphasized that, historically, significant announcements regarding medical topics have undergone rigorous review and consensus-building among experts. The current situation, he suggested, represents a departure from this established process.
The politicization of medicine, as highlighted by Dr. Sirota, raises concerns about the erosion of evidence-based healthcare. The study’s findings serve as a reminder of the importance of relying on scientific evidence and expert guidance when making healthcare decisions, particularly during pregnancy. The situation also illustrates the potential for misinformation to influence patient behavior and prescribing practices, even in the face of established medical consensus.
The study’s findings come after a period of increased scrutiny of health policy under the current administration. , President Trump and Secretary of Health and Human Services Robert F. Kennedy Jr. Announced initiatives related to autism, focusing on leucovorin research and cautioning against Tylenol use. These actions have sparked debate and criticism from medical professionals, who emphasize the importance of evidence-based medicine and the potential harm of disseminating unverified information.